| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Neoplasms | 12 | 2023 | 227 | 5.580 |
Why?
|
| Ovarian Neoplasms | 12 | 2023 | 744 | 4.020 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 6 | 2023 | 18 | 3.500 |
Why?
|
| Endometrial Neoplasms | 6 | 2023 | 193 | 2.940 |
Why?
|
| Biomarkers, Tumor | 13 | 2022 | 1464 | 2.660 |
Why?
|
| Carcinoma, Endometrioid | 5 | 2023 | 43 | 2.660 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 3 | 2021 | 9 | 2.250 |
Why?
|
| Immunohistochemistry | 14 | 2021 | 1753 | 2.050 |
Why?
|
| DNA Mismatch Repair | 4 | 2023 | 52 | 1.650 |
Why?
|
| Genital Neoplasms, Female | 3 | 2022 | 107 | 1.610 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2021 | 11 | 1.580 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2022 | 62 | 1.570 |
Why?
|
| Myofibroma | 2 | 2020 | 3 | 1.400 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2022 | 42 | 1.350 |
Why?
|
| Adenoma | 2 | 2022 | 235 | 1.340 |
Why?
|
| Adnexal Diseases | 2 | 2019 | 17 | 1.220 |
Why?
|
| Carcinoma | 3 | 2022 | 436 | 1.190 |
Why?
|
| Female | 42 | 2023 | 44534 | 1.180 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2021 | 54 | 1.150 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2016 | 22 | 1.090 |
Why?
|
| Sarcoma, Endometrial Stromal | 2 | 2023 | 8 | 1.080 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 6 | 1.030 |
Why?
|
| Teratoma | 2 | 2023 | 50 | 1.010 |
Why?
|
| Endometrial Stromal Tumors | 2 | 2023 | 4 | 1.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 47 | 1.000 |
Why?
|
| Nuclear Receptor Coactivator 2 | 2 | 2021 | 15 | 0.970 |
Why?
|
| Adenocarcinoma | 2 | 2022 | 1169 | 0.900 |
Why?
|
| Leiomyoma | 2 | 2017 | 191 | 0.890 |
Why?
|
| Broad Ligament | 1 | 2022 | 1 | 0.870 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2022 | 2 | 0.870 |
Why?
|
| Ribonuclease III | 2 | 2022 | 14 | 0.860 |
Why?
|
| Leiomyosarcoma | 1 | 2022 | 40 | 0.830 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2022 | 62 | 0.820 |
Why?
|
| Humans | 43 | 2023 | 86645 | 0.820 |
Why?
|
| Middle Aged | 23 | 2022 | 25028 | 0.810 |
Why?
|
| Krukenberg Tumor | 2 | 2018 | 3 | 0.810 |
Why?
|
| Smooth Muscle Tumor | 1 | 2021 | 4 | 0.810 |
Why?
|
| Adult | 21 | 2022 | 25648 | 0.790 |
Why?
|
| Fibronectins | 1 | 2021 | 93 | 0.780 |
Why?
|
| Angiofibroma | 1 | 2020 | 4 | 0.770 |
Why?
|
| Vulvar Neoplasms | 1 | 2020 | 20 | 0.760 |
Why?
|
| Glioma | 1 | 2023 | 285 | 0.760 |
Why?
|
| Myxoma | 1 | 2020 | 28 | 0.760 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2018 | 348 | 0.750 |
Why?
|
| Polyps | 1 | 2020 | 28 | 0.750 |
Why?
|
| DNA-Binding Proteins | 5 | 2023 | 1208 | 0.740 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2019 | 30 | 0.730 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 12 | 0.720 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 302 | 0.720 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 127 | 0.700 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 69 | 0.690 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2018 | 8 | 0.680 |
Why?
|
| Epithelioid Cells | 1 | 2018 | 13 | 0.670 |
Why?
|
| Aged | 15 | 2022 | 18415 | 0.640 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 645 | 0.620 |
Why?
|
| Fumarate Hydratase | 1 | 2017 | 6 | 0.620 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2018 | 157 | 0.590 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 2903 | 0.570 |
Why?
|
| Progestins | 1 | 2016 | 22 | 0.560 |
Why?
|
| DNA Repair Enzymes | 1 | 2016 | 52 | 0.550 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 696 | 0.540 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 3 | 0.540 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2023 | 33 | 0.540 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 3 | 2023 | 23 | 0.540 |
Why?
|
| Diagnosis, Differential | 7 | 2022 | 1565 | 0.530 |
Why?
|
| Ovary | 2 | 2021 | 258 | 0.530 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2015 | 28 | 0.530 |
Why?
|
| Ataxia Telangiectasia | 1 | 2015 | 11 | 0.530 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 153 | 0.530 |
Why?
|
| Premenopause | 1 | 2015 | 54 | 0.520 |
Why?
|
| Parotid Gland | 1 | 2015 | 31 | 0.510 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 50 | 0.500 |
Why?
|
| Postmenopause | 1 | 2015 | 98 | 0.500 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 114 | 0.490 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 302 | 0.490 |
Why?
|
| Testosterone | 1 | 2015 | 271 | 0.480 |
Why?
|
| Skin Diseases | 1 | 2015 | 166 | 0.470 |
Why?
|
| Prognosis | 8 | 2022 | 3680 | 0.470 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 357 | 0.460 |
Why?
|
| Young Adult | 6 | 2021 | 5976 | 0.410 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6509 | 0.370 |
Why?
|
| Urethral Stricture | 2 | 2019 | 13 | 0.350 |
Why?
|
| Gene Fusion | 2 | 2020 | 38 | 0.350 |
Why?
|
| Mutation | 4 | 2021 | 3968 | 0.350 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 275 | 0.340 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 170 | 0.310 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 239 | 0.280 |
Why?
|
| Adolescent | 4 | 2021 | 8982 | 0.280 |
Why?
|
| Biopsy | 3 | 2019 | 1163 | 0.270 |
Why?
|
| Child | 3 | 2023 | 6928 | 0.260 |
Why?
|
| Cervix Uteri | 3 | 2022 | 65 | 0.250 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 1673 | 0.250 |
Why?
|
| Oncogene Fusion | 2 | 2021 | 8 | 0.240 |
Why?
|
| Tissue Array Analysis | 2 | 2021 | 124 | 0.240 |
Why?
|
| Necrosis | 1 | 2023 | 204 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 860 | 0.230 |
Why?
|
| Lichen Sclerosus et Atrophicus | 2 | 2019 | 7 | 0.220 |
Why?
|
| Incidence | 2 | 2019 | 1577 | 0.220 |
Why?
|
| Adenosarcoma | 1 | 2022 | 3 | 0.220 |
Why?
|
| Phenotype | 2 | 2019 | 2378 | 0.220 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 18 | 0.220 |
Why?
|
| Wolffian Ducts | 1 | 2022 | 7 | 0.220 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2022 | 5 | 0.210 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2021 | 8 | 0.200 |
Why?
|
| Hemorrhage | 1 | 2023 | 268 | 0.200 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 45 | 0.200 |
Why?
|
| Cystadenoma, Papillary | 1 | 2021 | 8 | 0.200 |
Why?
|
| SMARCB1 Protein | 1 | 2021 | 13 | 0.200 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2021 | 24 | 0.200 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2021 | 20 | 0.200 |
Why?
|
| Urogenital Neoplasms | 1 | 2021 | 23 | 0.200 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2020 | 4 | 0.200 |
Why?
|
| Genitalia, Female | 1 | 2020 | 25 | 0.190 |
Why?
|
| Vulva | 1 | 2020 | 23 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 128 | 0.190 |
Why?
|
| DNA Helicases | 1 | 2021 | 79 | 0.190 |
Why?
|
| Immunophenotyping | 1 | 2020 | 211 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2271 | 0.180 |
Why?
|
| Papillomaviridae | 2 | 2022 | 153 | 0.180 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2019 | 11 | 0.180 |
Why?
|
| Sarcoma | 1 | 2021 | 215 | 0.170 |
Why?
|
| Gene Dosage | 1 | 2019 | 207 | 0.170 |
Why?
|
| Urethra | 1 | 2019 | 113 | 0.170 |
Why?
|
| Pregnancy | 2 | 2016 | 2894 | 0.160 |
Why?
|
| Mitosis | 1 | 2018 | 153 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2023 | 8491 | 0.160 |
Why?
|
| Genomics | 1 | 2023 | 720 | 0.150 |
Why?
|
| Tumor Burden | 1 | 2018 | 289 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1313 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 426 | 0.150 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2016 | 27 | 0.140 |
Why?
|
| Boston | 1 | 2016 | 33 | 0.140 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2016 | 131 | 0.140 |
Why?
|
| Salpingectomy | 1 | 2015 | 3 | 0.140 |
Why?
|
| California | 1 | 2016 | 138 | 0.140 |
Why?
|
| Penicillamine | 1 | 2015 | 12 | 0.140 |
Why?
|
| Voice Disorders | 1 | 2015 | 8 | 0.140 |
Why?
|
| Elastic Tissue | 1 | 2015 | 18 | 0.140 |
Why?
|
| Inflammation | 1 | 2021 | 920 | 0.140 |
Why?
|
| Luteinization | 1 | 2015 | 1 | 0.140 |
Why?
|
| Alopecia | 1 | 2015 | 34 | 0.140 |
Why?
|
| Hirsutism | 1 | 2015 | 61 | 0.130 |
Why?
|
| Ovariectomy | 1 | 2015 | 81 | 0.130 |
Why?
|
| Hyperplasia | 1 | 2015 | 148 | 0.130 |
Why?
|
| Scleroderma, Systemic | 1 | 2015 | 43 | 0.130 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 1939 | 0.130 |
Why?
|
| Septum of Brain | 2 | 2005 | 2 | 0.130 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 54 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2016 | 143 | 0.130 |
Why?
|
| Ovarian Diseases | 1 | 2015 | 32 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 16 | 0.130 |
Why?
|
| Parasympathetic Nervous System | 2 | 2005 | 33 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 123 | 0.130 |
Why?
|
| Fibroma | 1 | 2015 | 33 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2015 | 107 | 0.130 |
Why?
|
| Endometriosis | 1 | 2015 | 58 | 0.130 |
Why?
|
| Estradiol | 1 | 2015 | 252 | 0.130 |
Why?
|
| Extremities | 1 | 2015 | 167 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2021 | 1565 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 336 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 2705 | 0.100 |
Why?
|
| Insulin | 1 | 2015 | 1160 | 0.090 |
Why?
|
| Axotomy | 2 | 2005 | 8 | 0.080 |
Why?
|
| Time Factors | 1 | 2016 | 5210 | 0.070 |
Why?
|
| Capsid Proteins | 1 | 2005 | 32 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2005 | 63 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2438 | 0.060 |
Why?
|
| Polyethyleneimine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Nerve Growth Factor | 1 | 2004 | 17 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2005 | 439 | 0.060 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 152 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 3640 | 0.060 |
Why?
|
| Male | 5 | 2021 | 40967 | 0.060 |
Why?
|
| Co-Repressor Proteins | 1 | 2023 | 18 | 0.060 |
Why?
|
| Biomarkers | 2 | 2019 | 1718 | 0.060 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2021 | 15 | 0.050 |
Why?
|
| Uterus | 1 | 2023 | 215 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2022 | 526 | 0.050 |
Why?
|
| beta Catenin | 1 | 2022 | 251 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2021 | 503 | 0.050 |
Why?
|
| Point Mutation | 1 | 2021 | 246 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2023 | 403 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 91 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2021 | 853 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 456 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 378 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 597 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 2016 | 38 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 1139 | 0.040 |
Why?
|
| Vaginal Smears | 1 | 2016 | 68 | 0.040 |
Why?
|
| Neurons | 1 | 2004 | 1546 | 0.030 |
Why?
|
| Vagina | 1 | 2016 | 161 | 0.030 |
Why?
|
| Stereotaxic Techniques | 2 | 2005 | 69 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2022 | 2262 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 305 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1384 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1219 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 4213 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 3990 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2019 | 7993 | 0.020 |
Why?
|
| Fornix, Brain | 1 | 2005 | 2 | 0.020 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2005 | 23 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2005 | 268 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 376 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2004 | 72 | 0.020 |
Why?
|
| Transgenes | 1 | 2004 | 180 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 144 | 0.010 |
Why?
|
| Animals | 2 | 2005 | 26582 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 11352 | 0.010 |
Why?
|